Improving SARS-CoV-2 vaccine response is challenging in chronic lymphocytic leukaemia

Affiliations

Comment

Francesca Romana Mauro. Lancet Haematol. 2025 Apr.

. 2025 Apr;12(4):e238-e239.

doi: 10.1016/S2352-3026(25)00069-9.

¹ Haematology, Department of Translational and Precision Medicine, Sapienza University, Rome, Italy. Electronic address: mauro@bce.uniroma1.it.

No abstract available

Conflict of interest statement

I declare no competing interests.

A 3-week pause versus continued Bruton tyrosine kinase inhibitor use during COVID-19 vaccination in individuals with chronic lymphocytic leukaemia (IMPROVE trial): a randomised, open-label, superiority trial.
Cook JA, Patten PEM, Peckham N, Moss P, Phillips N, Abhishek A, Roberts T, Hodges M, Talbot G, Barber V, Francis A, Shields AM, Duley L, Hoogeboom R, Willett BJ, Scott S, Parry-Jones N, Eyre TA, Plested G, Vandici G, Wandroo FA, Hutchinson C, Paneesha S, Murray DJ, Martinez-Calle N, Jenkins S, Heartin E, Parry HM. Cook JA, et al. Lancet Haematol. 2025 Apr;12(4):e294-e303. doi: 10.1016/S2352-3026(25)00008-0. Lancet Haematol. 2025. PMID: 40175001 Clinical Trial.